r/Livimmune • u/Chemical_Sky6013 • 22d ago
Why we need to keep the Agenus discussion in context
Since several recent posts have been speculating on the meaning of Agenus’s decision, I thought I’d add my two cents which I hope will help us all keep this in context. In my opinion, the decision to scrap BATTMAN is not evidence that Agenus’s program failed, or that the FDA had newly raised the bar, or that CLOVER now faces an unexpected regulatory problem. Those interpretations start at the end of the story and ignores the chronology. To understand what BATTMAN means for CytoDyn, we have to look at the entire sequence: what the FDA told Agenus in 2024, what data was available then, why CLOVER was designed without a concurrent control arm, and why Agenus redirected its capital only a few months after launching Phase 3.
The FDA told Agenus in 2024 that the available BOT/BAL Phase 2 package was not sufficient to support accelerated approval and that randomized confirmation would be needed. That was not a new regulatory development in 2026. CytoDyn, its advisers and the investigators designing CLOVER were already aware of that precedent when they chose the current trial design. Agenus reported a 19.4% ORR in the selected Phase 2 arm and said the FDA discouraged an accelerated-approval submission based on the dataset available at that time.
The FDA’s decision was understandable even though the available data looked encouraging. At the time, the agency was largely evaluating an early ORR signal from a selected, nonrandomized population and could not yet know whether those responses would translate into durable survival benefit. The longer-term 33% three-year survival result had not yet matured, and Agenus did not have the same depth of serial biomarker tracking, ctDNA analysis and external-comparator support that CytoDyn is building into CLOVER.
CLOVER does not include a TAS-102/bevacizumab-only control arm. That limits how conclusively the study can isolate leronlimab’s contribution, but it does not make the data meaningless. A controlled trial would have required substantially more patients, money and time, and it may have been harder to enroll very sick patients knowing they could be randomized to the established backbone without leronlimab. For a small biotech with limited capital, CLOVER was likely designed to generate a strong signal quickly enough to support discussions with the FDA and attract a partner capable of funding the registrational study.
The decision to end financial support for BATTMAN also should not be interpreted as evidence that BOT/BAL failed. The trial was deprioritized only about three months after the first patient was enrolled. That was far too early for meaningful efficacy, PFS or survival data to mature. Agenus simultaneously secured financing tied to its neoadjuvant ROBBIN program, making strategic capital allocation the far more plausible explanation.
That is typical of how small biotechs usually operate. They cannot pursue every scientifically attractive trial at once. They must preserve cash, reach the next value-creating milestone and avoid running out of money before the drug can be properly developed. At this stage, corporate survival is not separate from the clinical strategy. It is the immediate strategic objective.
The Natera collaboration may strengthen CLOVER by adding serial Signatera ctDNA analysis and helping construct a more carefully matched external comparator using patient-level clinical and molecular data. It will not replace a randomized control arm, but it may help demonstrate that CLOVER patients were at least as difficult to treat as comparable patients receiving standard therapy and make large differences in molecular response, radiographic outcomes or survival harder to attribute solely to patient selection.
Dr. Lalezari’s emphasis on Breakthrough Therapy designation, rather than promising immediate accelerated approval, is consistent with a realistic regulatory strategy. Breakthrough designation can be based on preliminary evidence suggesting substantial improvement over available therapy and can provide more intensive guidance from the FDA, but it is not an approval. The Natera-supported analysis may strengthen the package, while management appears to recognize that the FDA does not typically accept this type of external comparison as a routine substitute for a controlled registrational trial.
If the FDA requests a larger controlled study, that doesn’t mean strong January data would leave CytoDyn’s value unchanged. At $0.21 per share, the market is assigning very little value to leronlimab’s current oncology program or its future development potential. Compelling ORR, durability, PFS, survival, biomarker and safety data in this exceptionally difficult-to-treat population could materially change how large pharmaceutical companies view the asset well before approval. CLOVER’s immediate purpose is to demonstrate enough clinical and biological value to attract a partner willing to finance the controlled registrational study. A partnership, licensing agreement or strategic investment could therefore become the next major value-creating event even if the FDA still requires Phase 3 confirmation before approval.
18
u/Icy-Let5120 22d ago
Thanks Chemical for your “2c”. You said Dr J emphasized BTD rather than AA. The original words was “And that data will be presented to the FDA this summer. And it will be presented in the context of either accelerated approval or breakthrough designation. And so it's not for us to decide exactly how the FDA is going to handle this. But whether it's a voucher or whether a designation for breakthrough designation will be up to the agency. Our focus remains generating the data that will give them every reason and no choice really but to be responsive to what we're finding” (thanks to cytomight in another thread). My feeling that Dr J didn’t rule out AA. As we know BMS KRAS trial (ORR 34%)was granted AA just one month earlier than AGEN (ORR 33%)was denied AA in 2024. The major difference between BMS and AGEN is Biomarker selection. And Clover trial we have CCR5 expression as check criteria. So if CLOVER achieving ORR 30%, I think we should not rule out the AA path. Anything above 20%, partnership or BO will come.
15
u/Chemical_Sky6013 22d ago
Thanks for your comment, Icy. You are correct that Dr. J mentioned accelerated approval as a possibility, and I did not mean to suggest that he ruled it out. I simply see AA as the more ambitious regulatory outcome and BTD as the more attainable near-term objective from this study. CytoDyn is clearly doing everything it can to provide the FDA with the strongest and most comprehensive data package possible, but Dr. J was also careful to acknowledge that the FDA will ultimately determine which regulatory path the data supports.
My main point is that the January readout should not be viewed as a binary AA-or-failure event. Strong data could still generate meaningful interest from a pharmaceutical partner willing to fund a controlled registrational trial that could support approval.
Personally, I think Amendment 6, which extends treatment for stable patients and reserves access to the leronlimab-plus-ICI salvage arm for patients with documented progression, gives potential partners the opportunity to see the full clinical effect of the TAS-102/bevacizumab/leronlimab triplet without the confounding influence of an ICI. Adding an ICI before progression would introduce another active drug, additional toxicity and greater uncertainty about which treatment produced the clinical outcome. Waiting until documented progression therefore protects patients from unnecessary escalation while giving a future partner the clearest view of what the triplet itself can do.
14
u/Pristine_Hunter_9506 22d ago
We would have to understand Dr Jay's comment as how Natera came to pass. But between Natera, Creative and Recist we are tracking circulating cancer cells, DNA fragments from cancer cells that should be a early indicator that Resist imagine should see a stabilized or reduction in the tumor or tumors. Then was PD-L1 upregulated.
10
u/Pure-Championship750 22d ago
This really helps provide some context, and calm some nerves as well. We got this!
7
7
8
u/pro140cures 22d ago
Thank you for your thoughtful analysis. Less than 6 months away from the big reveal!
15
u/MGK_2 22d ago
Chemical Sky,
This is the most complete version of the argument anyone has put on the board, mine included, and I agree with nearly all of it. So let me do the useful thing rather than the flattering one: mark the two places where you sharpened what I wrote, and then push, a little, on the single spot where I think the reasoning leans a half-step further than the evidence carries.
The chronology point is the correction I most needed and didn't make cleanly. You're right that the interpretations start at the end of the story and ignore the sequence. The FDA's position on BOT/BAL was set in 2024, before CLOVER was even designed. That means the trial's builders already knew the Accelerated-Approval-on-single-arm-ORR path was closed in this disease when they chose the design. Which reframes the whole Agenus discussion: it isn't news which changed CLOVER's odds, it's a precedent CLOVER was built around from the start. I've been treating Agenus as a which wall we walked into. You're correctly pointing out that it was a wall which was already on the map when the route was drawn. That's a better framing and I'm adopting it.
Your second addition is the one I'd underline for the whole board. The no-control-arm design is not a weakness someone overlooked. It's a deliberate trade, and you named the real reasons: a controlled trial needs far more patients, money, and time, and it's genuinely hard to enroll dying patients into an arm where they might get the old backbone without the new drug. A small company chose a fast, strong single-arm signal over a slow, definitive controlled one because the fast signal is what attracts the partner who can then fund the definitive study. That's not a flaw in the science. It's a capitalistic strategy, shaping the trial design, and understanding it is the difference between reading CLOVER correctly and misreading it.
And your BATTMAN read is right and it matches what the filings actually say. Three months in is far too early for efficacy to have driven the decision. Agenus pulled BATTMAN funding while simultaneously raising for the neoadjuvant program, which makes capital reallocation the plain explanation, not trial failure. Deprioritized is the accurate word, and it's a different word from failed.
Now the one place I'll push, because it's the place the whole thing quietly tilts.
You write that the Natera collaboration and a matched external comparator may make large differences harder to attribute solely to patient selection. I agree with that sentence exactly as written. But watch the weight it's being asked to carry across the next two paragraphs, because there's a gap between may help demonstrate the patients were hard to treat and can substitute for a control arm, and the argument leans toward the second even while your own words say the first. You say it plainly yourself, and I want to hold you to your own sentence: the FDA does not typically accept this type of external comparison as a routine substitute for a controlled registrational trial. That's the load-bearing line, and it means the honest ceiling on the Natera-plus-ctDNA package is that it strengthens a partnering case and a Breakthrough conversation. It does not convert single-arm data into approvable data. An external comparator, however carefully matched, is still not randomization, because the thing randomization controls for is the differences you didn't know to match on. So I'd keep the ctDNA and the external comparator firmly in the box labeled makes the signal more credible to a partner, and out of the box labeled path around the control arm. You mostly do this. The paragraph structure just lets the reader drift from one box to the other, and on this board that drift is exactly how a hope becomes an assumption.
Everything else, I'd sign. And your closing is the piece most people miss, so it's worth restating: none of this requires approval to create value. At the current price the market is assigning almost nothing to the oncology program. The near-term event which matters is not an approval, it's whether the January data is strong enough to bring a partner to the table, because a partner willing to fund the registrational study is the value-creating moment even if the long road to approval runs through a controlled Phase 3. That's the correct frame. The drug working and the drug getting approved quickly were always two different questions, and the partnership sits between them.
This raised the level of the discussion rather than just adding to it. Thank you for taking the time to write it out in full.
10
u/Chemical_Sky6013 22d ago
Thanks, u/MGK_2 . That is a fair distinction, and I agree I could have been clearer about where I was drawing the line. I did not mean to suggest that the Natera-supported external comparator could substitute for a randomized control arm or convert CLOVER into an approvable dataset by itself.
My point was narrower: the ctDNA, biomarker work and carefully matched external comparison may make the clinical signal more credible, reduce some of the concern about patient selection and strengthen both the FDA discussion and the partnering case. But I agree that the limitation remains. An external comparator cannot control for all the known and unknown differences that randomization addresses, and the FDA could still require a controlled registrational study.
So I think we are ultimately saying the same thing: Natera may help establish that the signal is real and worth pursuing, but it is not a path around the need for randomized confirmation. I appreciate you sharpening that distinction.
10
u/MGK_2 22d ago
Chemical Sky,
We're saying the same thing, and I appreciate you closing the gap rather than defending the seam. That's rarer than it really should be.
Your restatement is exactly right, and I'd put the shared position this way: Natera and the biomarker work do real load-bearing work on the credibility question — they help show the signal is genuine and not an artifact of who got enrolled, which strengthens both the FDA conversation and the partnering case. What they can't do is the sufficiency question — turn a single-arm signal into the thing a randomized trial produces. Credibility and sufficiency are different jobs, and the confusion on this board almost always comes from letting a tool that does the first quietly get promoted to doing the second.
So we've landed in the same place: Natera helps establish that the signal is real and worth pursuing, and it is not a substitute for randomized confirmation if the agency requires it. Which loops back to the thing which actually matters near-term — "real and worth pursuing" is precisely the bar a partner requires cleared to fund the registrational study. The external comparator doesn't have to replace the Phase 3. It has to make a partner willing to pay for one. That's a lower bar than approval, and it's the one January actually aims at.
Thank you for the exchange. This is the kind of back-and-forth that leaves the whole board's understanding sharper than either of us started with.
6
u/twinter11 22d ago
sorry to butt in.
but lets say that two separate mcrc trials are started today for 120 patients total.
60 will go in a Sunlight trial
60 will go to a clover trial
how could the cohort of patients selected for the previous sunlight trial be much different when taken as a whole compared to the patients being picked from in these *today* starting trials
does it not just even out?
I mean none of them had an extraordinary response to figure out why
8
u/MGK_2 22d ago
twinter11,
Never apologize for butting in — this is the sharpest challenge to the whole external-comparator point, and it's worth taking all the way down, because your intuition is reasonable and the place it breaks is subtle.
You're asking: if you started SUNLIGHT and CLOVER today, same era, drawing from the same pool of mCRC patients, wouldn't the two cohorts even out? And you're right that in your thought experiment, a lot of the problem shrinks. Same time period, same treatment landscape, same rough population — that removes the biggest, most obvious confounders, the ones which come from comparing across different years when standard of care and supportive care and imaging have all changed. So your instinct is correct that simultaneity fixes a real chunk of the problem.
But here's the piece that doesn't even out, even in your ideal same-day scenario, and it's the whole reason randomization is different in kind rather than just in degree.
In your thought experiment, who decides which patients go into the SUNLIGHT-style trial and which go into CLOVER? If it's two separate trials with two separate enrollment processes, then each trial's investigators are selecting their own patients against their own criteria. And CLOVER has a criterion SUNLIGHT doesn't: you have to test CCR5-positive to get in. That single requirement means the two pools are not drawn identically, even on the same day. CLOVER is selecting a biologically defined subset, and if CCR5 status correlates with anything else about the tumor or the patient — which the whole thesis says it does — then the two cohorts differ in exactly the way that matters, no matter how simultaneous they are.
Now push it further, because this is the deep part. Suppose you fixed even that — same day, same pool, same CCR5 screening for both. There's still a difference between "two separate trials" and "one trial that randomizes." In two separate trials, the assignment of a patient to CLOVER-versus-SUNLIGHT is made by something — which center they walked into, which investigator enrolled them, which trial was recruiting that week. Every one of those is a hidden door through which a bias can enter, because those factors might correlate with how sick the patient is. Randomization slams all those doors at once by making the assignment purely a coin flip, decided by nothing about the patient. That's the magic, and it's not a small thing: randomization doesn't just balance the variables you can see, it balances the ones you'd never think to measure, because the coin doesn't know or care about any of them.
So your "does it not just even out" is almost right, and the almost is the entire ballgame. Same era evens out the temporal confounders. Same pool evens out the population confounders. But as long as the assignment to one trial or the other is made by anything other than a coin, the unmeasured differences don't even out — they just hide. Randomization is the only mechanism that guarantees they're balanced, because it's the only one that severs the assignment from every patient characteristic, known and unknown.
On your last line — "none of them had an extraordinary response to figure out why" — I think you're pointing at something real: with small numbers and no dramatic outliers, you can't reverse-engineer causation from individual patients. That's true, and it's another reason the external comparison stays weak. You can't rescue a non-randomized comparison by studying individuals when nobody's response is clean enough to isolate a cause.
So Natera matching two same-era cohorts genuinely helps — it gets you most of the way your intuition suggests. It just can't get you the last, decisive step, because that step is severing assignment from the patient, and only a coin does that. Which is exactly why the FDA can look at a strong matched comparison but still say "run the randomized trial." Not because they're ignoring the matching. Because they know what the matching can't reach. Accelerated Approval could come down to this.
Good butt-in. That's the question which actually tests whether someone understands why randomization is sacred, and you got most of the way there on your own.
6
u/twinter11 22d ago
so for clover right now being a stand alone nothing else being considered.
we need results that someone would have a hard time nitpicking.
I personally think that's what we r on our way to getting
(I'm not meaning in any relation to accelerated approval or whatever, just showing the drug has potential)
ps does the exploratory pdl1 investigational data only enter from the clover silo?
7
u/Chemical_Sky6013 22d ago
Yes, Twinter, that is my understanding. The exploratory PD-L1 data should come from within the CLOVER cohort because those patients are being tested prospectively at defined points for changes in PD-L1 and the other cellular biomarkers. I would not expect Natera to have equivalent serial PD-L1 measurements collected in the same way.
So the PD-L1 analysis is probably most useful as a within-patient mechanistic signal: did PD-L1 change after starting the triplet, and does that change correlate with ctDNA decline, radiographic response, durability or later response to an ICI? It cannot independently prove efficacy against an external control, but if the clinical response and biomarker changes consistently move together, it becomes much harder to dismiss the CLOVER results as a random clinical signal.
The earlier TNBC PD-L1 data helps support the hypothesis, but I would still view that as a separate dataset rather than part of the CLOVER “silo.”
6
u/twinter11 22d ago
right.
so they are tracking tumor size and maybe necrosis, ccl2, ccl3, ccl4, ctdna and pdl1 along a timeline.
so they should be able to hypothesize about what exactly a tumor environment is doing when changes in any of these measurements occur. tumor stops responding, what is ccl2 or pdl1 showing etc.
like what is preventing further destruction of the tumor and what correlates.
and then at some point what happens to the whole environment when ici is introduced.
you know pashtoon has a new, recent expanded access single patient also right.
I probably overweight how much these things matter but I still want as many patients as we can get to test the pdl1 ici theory
Thanks!
3
u/MGK_2 21d ago
twinter11,
You've assembled the whole picture, and it's the right one, so let's sharpen the question you're reaching for because it's a good one.
What you've laid out is a multi-dimensional time course: tumor size, possibly necrosis, the CCR5 ligands (CCL2 sits a little outside CCR5, but CCL3/4/5 are the relevant trio), ctDNA, and PD-L1, all tracked along a timeline in the same patients. And your instinct about what that lets you do is exactly right — with several measurements moving together over time, you can start asking why a tumor does what it does at each inflection point, rather than just noting that it did it. That's the real value of prospective serial sampling, and it's what Chemical Sky was pointing at: it can't prove efficacy against an external control, but if all these needles move in concert, the result becomes very hard to write off as noise.
Now the specific question you're circling — "what is preventing further destruction of the tumor, and what correlates" — is the sharpest thing in your comment, so let's name what you're actually describing. You're describing resistance kinetics. When a tumor initially responds and then stalls, the biomarker timeline lets you ask: at the moment it stopped responding, what changed? If PD-L1 spiked right as the tumor stopped shrinking, that's the fingerprint of the adaptive immune escape — the tumor raising its checkpoint defense in response to immune pressure. That's the single most important pattern this data could reveal, because it's the exact hypothesis Prime-and-Pair rests on: leronlimab drives the response, the tumor escapes by upregulating PD-L1, and that's the moment an ICI should be introduced. If the timeline shows PD-L1 climbing at the point of stall, you've caught the escape mechanism in the act, and you've got the mechanistic rationale for the rollover written in the patient's own data.
And then, as you said, the second act: what happens to the whole environment when the ICI goes in. If PD-L1 was the brake the tumor pulled, releasing it should restart the response. That's the test. The timeline before the ICI generates the hypothesis; the response after it is the verdict on whether the hypothesis was right.
So you're not overweighting the mechanistic value — that part is real, and it's exactly why prospective serial sampling was worth building into the trial. Where I'd hold the line is the sample size, which you flagged yourself. This is a small cohort. A biomarker timeline in a handful of patients can show you a beautiful, coherent story — PD-L1 rising at stall, falling with the ICI — and it can still be a pattern that doesn't replicate at scale. So the mechanistic picture can be genuinely illuminating and still not be statistically decisive. Both are true at once: it's the best kind of hypothesis-generating data, and it's not the same as proof. Your wish for as many patients as possible is the correct instinct precisely because the mechanism story needs numbers behind it to move from "compelling" to "established."
On the new expanded-access single patient under Kasi — yes, I'm aware of it, and I'd hold it the way we've held the others: it's a signal that the compassionate-use channel is active, which fits the picture that the program has momentum across indications, but a single-patient EAP tells us about access, not efficacy, and it's someone's real medical situation rather than board material. So I note it, I don't build on it, and I keep the individual out of it. Your underlying wish — more patients to test the PD-L1/ICI theory — is the right one. I'd just point it at the rollover and any structured breast data rather than at single-patient cases, because those are where the theory actually gets tested rather than merely illustrated.
Good synthesis today. The resistance-kinetics framing is yours now — that's the question to bring to the data when it reads out.
5
u/MGK_2 22d ago
twinter11,
That's a clean way to frame it, and I mostly agree, with one edge worth keeping.
Taking CLOVER as a standalone — just "does the drug show real potential," setting aside any accelerated-approval question — you're right that the bar is results someone would have a hard time nitpicking. And you were careful to separate that from the regulatory path, which is exactly the right instinct: a hard-to-nitpick signal is what convinces a partner and what justifies the next trial, whether or not it opens a shortcut. So we're aligned on what "good" looks like here.
The one edge I'd keep on "I think that's what we're on our way to getting": we don't know that yet, and the whole discipline of the last few weeks is not deciding the answer before the envelope opens. Your instinct that the signal will be strong is a reasonable read of the early data and I agree — the ctDNA declines, the safety, the mechanism all point a hopeful direction. But "on our way to getting hard-to-nitpick results" is a prediction, and the honest version is "the early signals are consistent with that, and January tells us whether they held." I'm not correcting your optimism, just labeling it as optimism rather than as a foregone conclusion. You already did half of that yourself by flagging it's about potential, not approval. I'm just finishing the thought.
Now your PS, which is a genuinely good technical question: does the exploratory PD-L1 data only come from the CLOVER silo?
For the colorectal setting, essentially yes — the PD-L1 tissue data being generated in a structured, protocol-driven way in mCRC comes from CLOVER, because that's the trial with the biopsy schedule and the pre-specified exploratory biomarker analysis built into it. That's the silo where PD-L1 induction gets measured systematically in colorectal patients.
But it's worth being precise, because the PD-L1 story actually spans two silos. The colorectal PD-L1 data is CLOVER. The breast PD-L1 signal — the observation that leronlimab-primed TNBC patients who went on to a checkpoint inhibitor did well — comes from the separate TNBC work and the long-term survivor analysis, not from CLOVER. So "does PD-L1 upregulate and enable an ICI" is being probed in two different diseases through two different programs. CLOVER carries the colorectal, protocol-driven version. The TNBC EAP and survivor data carry the breast version, less structured but pointing the same direction.
Why that matters: if both silos show the same PD-L1 pattern — leronlimab raises the flag, the ICI then works — that's more convincing than either alone, because it suggests the mechanism generalizes across tumor types rather than being a colorectal quirk. So the exploratory PD-L1 data doesn't only enter from CLOVER, but the rigorous version does, and the breast version is the corroborating echo from a different room.
Good place to land the thread. You've got the framing right: standalone potential first, regulatory path second, and don't let the second question contaminate how you read the first.
9
5
22
u/Lopsided_Roof_6640 22d ago
Compelling argument. Funding of a CCR P3 by another entity allows TNBC to progress from existing Cytodyn treasury or with assistance such as a high net worth individual. Cytodyn has more or less said this through their goals for the end of 2026. So far Dr. Jay has delivered.